BioWorld Asia

Jan. 18, 2006

View Archived Issues

MorphoSys Boosts Antibody Work With $35M Acquisition

Expecting to triple the revenues from its research antibody division, MorphoSys AG is buying privately held Serotec Ltd. in a cash and stock deal valued at €29.3 million (US$35.3 million). (BioWorld International) Read More

UK Feeling Pressure After Fake Stem Cell Work In South Korea

Read More

Serotonin Receptor Regulator Has Pivotal Role In Depression

Read More

EU Orphan Applications To Benefit From Tighter Rules

Read More

Other News To Note

Read More